Validating InoCardia's WorkLoop Model To Support Discovery Safety Improvements

验证 InoCardia 的 WorkLoop 模型以支持发现安全改进

• 批准号: 103317
• 金额: $ 8.75万
• 依托单位: INOCARDIA LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=103317
• 关键词: Validating; InoCardia; WorkLoop; Model; Support

When drugs/chemicals are developed to treat a particular disease or for human use purposes they sometimes have side effects that cause damage to the heart. Occasionally these dangerous side effects are only recognised after the drug/chemical has been marketed & taken/used by thousands of people. This is a significant risk to human health & is costly to the pharmaceutical industry when a dangerous product is withdrawn from market. Although side effects of drugs can be caused by many things, one area of great concern is the effects of drugs on the force that heart muscle can produce during its role in pumping blood around the body. Many drugs developed to treat Cancer have a high risk of reducing the force of contraction of the heart, can lead to the development of heart failure & increased mortality. InoCardia has recently developed a successful heart contractility (inotropy) assessment assay (supported by InnovateUK & NC3R) which is now being adopted by the Pharma Industry to manage inotropy risk at the late pre-clinical stage of drug development. We aim to validate our highly predictive contractility assessment technology for use in the early chemistry phases of drug development and the ability to screen out the risk of causing contractility issues.

当开发药物/化学品来治疗特定疾病或用于人类使用时，它们有时会产生对心脏造成损害的副作用。有时，这些危险的副作用只有在药物/化学品上市并被成千上万的人服用/使用后才被认识到。这对人类健康是一个重大风险，当一种危险产品从市场上撤出时，对制药业来说是昂贵的。虽然药物的副作用可能由许多因素引起，但最令人关注的一个领域是药物对心肌在泵送血液过程中产生的力量的影响。许多开发用于治疗癌症的药物具有降低心脏收缩力的高风险，可导致心力衰竭的发展和死亡率增加。InoCardia最近开发了一种成功的心脏收缩力（收缩力）评估测定（由InnovateUK和NC 3R支持），目前已被制药行业采用，用于在药物开发的临床前后期阶段管理收缩力风险。我们的目标是验证我们高度预测性的收缩性评估技术，用于药物开发的早期化学阶段，并能够筛选出导致收缩性问题的风险。